Business Trends– category –
-
Sana Biotechnology Announces Groundbreaking 14-Month Durability Data for Hypoimmune-Modified Islet Cell Transplantation (UP421) in Type 1 Diabetes Without Immunosuppression, Published in The New England Journal of Medicine
GlobeNewswire (Sana Biotechnology) USA Overview Sana Biotechnology announced groundbreaking long-term durability data for its hypoimmune-modified islet cell transplant UP421 in Type 1 Diabetes patients, demonstrating 14 months of sustain... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
Century Therapeutics Unveils Preclinical Data for iPSC-Derived Islet Replacement Therapy CNTY-813 for Type 1 Diabetes, Aiming for Immunosuppression-Free Treatment via Allo-Evasion™ 5.0 Technology and H2 2026 IND Filing
GlobeNewswire (Century Therapeutics) USA Overview Century Therapeutics announced that preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, will be presented at EASD 2026 and the Breakthrough T1D ... -
Fate Therapeutics Secures FDA IND Clearance for FT839, a Dual iPSC-Derived CAR T-Cell Candidate, with Phase 1/2a Trial Targeting Autoimmune Diseases and Hematologic Malignancies to Commence in H2 2026
GlobeNewswire USA Overview Fate Therapeutics announced FDA IND clearance for FT839, its iPSC-derived dual CAR T-cell product candidate. FT839 is designed to simultaneously target CD19 and CD38, aiming for comprehensive treatment across a... -
Fate Therapeutics’ Off-the-Shelf iPSC-Derived CAR T-Cell Therapy FT819 Shows Promising Early Clinical Data in Treatment-Resistant Systemic Sclerosis
EurekAlert! USA Overview New preliminary clinical data for Fate Therapeutics' off-the-shelf iPSC-derived CAR T-cell therapy, FT819, was presented at ISSCR 2026, targeting patients with treatment-resistant systemic sclerosis. As part of a... -
Phase 1/2a Trial of Autologous iPSC-Derived Dopaminergic Progenitors for Parkinson’s Shows Positive 12-Month Interim Results in 8 Patients, Demonstrating Favorable Safety and Functional Improvement
International Society for Stem Cell Research USA Overview Interim clinical results from the first Phase 1/2a trial of autologous iPSC-derived dopaminergic progenitor cells for Parkinson's Disease were presented at ISSCR 2026, showing fav... -
Landmark Phase 1b/2a REGEN4HD Trial for Huntington’s Disease with Pluripotent Stem Cell-Derived Neural Stem Cells Unveiled at ISSCR 2026
International Society for Stem Cell Research International Overview The first clinical trial (Phase 1b/2a REGEN4HD study) of pluripotent stem cell-derived neural stem cells for Huntington's Disease was highlighted at the ISSCR 2026 annua... -
Databricks Secures Strategic Funding Round at $188 Billion Valuation to Accelerate AI Strategy, Including Unity AI Gateway and Genie
Databricks USA Overview Databricks announced a strategic funding round at an astounding $188 billion valuation, led by existing investor Coatue. This new capital will primarily accelerate the company's AI strategy, focusing on key produc... -
Takeda Partners with Insilico Medicine in $600 Million AI Drug Discovery Deal, Including $60 Million Upfront Payment
Fierce Pharma Asia USA Overview Takeda Pharmaceutical has signed a strategic partnership with AI drug discovery company Insilico Medicine, potentially valued at up to $600 million, including a $60 million upfront payment. Takeda will lev... -
Intel Announces €5 Billion Expansion in Ireland to Boost Next-Generation AI and Data Center Chip Production
Simply Wall St USA Overview Intel announced a €5 billion expansion of its Leixlip, Ireland campus to significantly increase output of next-generation AI and data center chips, including Intel Xeon 6 processors. This investment is part of...
